Dose-finding based on multiple toxicities in a soft tissue sarcoma trial, Journal of the American Statistical Association, vol.99, pp.26-35, 2004. ,
Simultaneously optimizing dose and schedule of a new cytotoxic agent, Clinical Trials, vol.4, pp.113-124, 2007. ,
Determining a maximum-tolerated schedule of a cytotoxic agent, Biometrics, vol.61, pp.335-343, 2005. ,
On the consistency of the continual reassessment method with multiple toxicity constraints, Journal of Statistical Planning and Inference, vol.164, pp.1-9, 2015. ,
dfcrm: Dose-Finding by the Continual Reassessment Method, 2013. ,
Simple benchmark for complex dose finding studies, Biometrics, vol.70, pp.389-397, 2014. ,
Sequential designs for phase i clinical trials with late-onset toxicities, Biometrics, vol.56, pp.1177-1182, 2000. ,
Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase i oncology clinical trials, Statistics in Medicine, vol.32, pp.5430-5447, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-00936325
Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities, Statistics in Medicine, vol.32, pp.2728-2746, 2013. ,
Dose finding for continuous and ordinal outcomes with a monotone objective function: a unified approach, Biometrics, vol.65, pp.307-315, 2009. ,
Model calibration in the continual reassessment method, Clinical Trials, vol.6, pp.227-238, 2009. ,
Case example of dose optimization using data from Bortezomib dose-finding clinical trials, Journal of Clinical Oncology, vol.34, pp.1395-1401, 2016. ,
Continual reassessment method with multiple toxicity constraints, Biostatistics, vol.12, pp.386-398, 2011. ,
Toxicity burden score: a novel approach to summarize multiple toxic effects, Annals of Oncology, vol.23, pp.537-541, 2012. ,
Parametric non-mixture cure models for schedule finding of therapeutic agents, Journal of the Royal Statistical Society: Series C (Applied Statistics), vol.58, pp.225-236, 2009. ,
Methodologic guidelines for the design of high-dose chemotherapy regimens, Biology of Blood and Marrow Transplantation, vol.7, pp.414-432, 2001. ,
Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Bethesda, Maryland: National Institutes of Health, 2009. ,
Continual reassessment method: a practical design for phase i clinical trials in cancer, Biometrics, vol.46, pp.33-48, 1990. ,
Dose finding with longitudinal data: simpler models, richer outcomes, Statistics in Medicine, vol.34, pp.2983-2998, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01288874
R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, 2013. ,
Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study, Annals of Oncology, vol.21, pp.2233-2239, 2010. ,
Design and analysis of phase I clinical trials, Biometrics, vol.45, pp.925-937, 1989. ,
Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading, Statistics in Medicine, vol.30, pp.2070-2080, 2011. ,
Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method, Clinical Trials, vol.9, pp.303-313, 2012. ,
The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach, Biometrics, vol.63, pp.173-179, 2007. ,